U.S. Markets close in 1 hr 43 mins

Nuvo Pharmaceuticals™ Announces 2018 Second Quarter Results

- Reports $1.9 million of Adjusted EBITDA on $5.9 million of Revenue -
- Finished the Quarter with $8.7 million of Cash and no Debt -

- Nuvo to Host Conference Call/Audio Webcast August 2 nd at 8:30 a.m. ET -

MISSISSAUGA, ON , Aug. 2, 2018 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced its financial and operational results for the second quarter ended June 30 , 2018.  For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements which are available on the Company's website (www.nuvopharmaceuticals.com). All figures are in Canadian dollars, unless otherwise noted.

Nuvo Pharmaceuticals Inc. (CNW Group/Nuvo Pharmaceuticals Inc.)

Second Quarter 2018 Highlights and Business Update

  • On June 18, 2018 , the Company's licensing partner for Pennsaid® 2% in Switzerland and Lichtenstein, Gebro Pharma AG (Gebro Pharma), received notification from Swissmedic that Gebro Pharma could submit the Pennsaid 2% marketing authorization application in Switzerland during the third quarter of 2018 which triggered a milestone payment from Gebro Pharma to the Company.

  • On June 18, 2018 , the Company received notification from the Austrian Medicines and Medical Devices Agency (AGES), that the Company could submit its marketing authorization application for Pennsaid 2% during the fourth quarter of 2018. The Company intends to submit this application to AGES during the fourth quarter as instructed.

  • On July 23, 2018 , the Company announced its wholly owned subsidiary Nuvo Pharmaceuticals ( Ireland ) Limited (Nuvo Ireland) had entered into a license and supply agreement with Fagron Belgium NV (Fagron) for Resultz®. The license agreement grants Fagron the commercialization rights to Resultz in Belgium , the Netherlands and Luxembourg (BeNeLux or the Territory) as a class one medical device for the human treatment of head lice infestation. Resultz is already cleared for marketing in the Territory. Nuvo Ireland received upfront consideration, will receive royalties on net sales of Resultz in the Territory and will earn revenue from Fagron pursuant to an exclusive supply agreement.

  • Pursuant to the Company's notice of intention to make a normal course issuer bid for a portion of its outstanding common shares, the Company purchased 229,394 common shares with available cash on hand for a total cost of $729,659 or $3.18 per share. The common shares acquired by Nuvo were cancelled.


Second Quarter Financial Summary 

  • Total revenue was $5.9 million for the three months ended June 30, 2018 compared to $3.1 million for the three months ended June 30, 2017 .

  • Adjusted EBITDA(1) was $1.9 million for the three months ended June 30, 2018 compared to $(0.1) million for the three months ended June 30, 2017 .

  • Net income was $1.1 million for the three months ended June 30, 2018 compared to $(0.2) million for the three months ended June 30, 2017 . Net income was inclusive of non-cash amortization expense of $0.5 million related to the Resultz patents.

  • Cash and short-term investments were $8.7 million as at June 30, 2018 compared to $6.5 million as at March 31, 2018 .


(1) Adjusted EBITDA is a non- International Financial Reporting Standards (IFRS) financial measure defined by the Company below.

 

"The improved year-over-year financial results reflect the return of Pennsaid 2% physician sample production and more consistent Pennsaid 2% commercial bottle production at our manufacturing facility for our U.S. partner, Horizon Pharma.  The Nuvo team made considerable progress towards Pennsaid 2% regulatory submissions in the E.U. and Switzerland planned for later this year.  And finally, our Resultz partnering efforts are beginning to yield results with the announcement of our first licensing transaction with Fagron in the BeNeLux region," said Jesse Ledger , Nuvo's President and CEO. 

Growth Strategy
The Company's focus, in the short-term, is to continue to maximize the value of Pennsaid 2% and Resultz through out-licensing to commercial partners in international markets, identifying new opportunities to acquire additional, revenue generating or late-stage products or businesses to further diversify the Company's existing product portfolio and revenue streams and to better utilize the Company's manufacturing facility in Varennes , Québec.

Table of Selected Financial Results
For further details on the results, please refer to Nuvo's MD&A and the Condensed Consolidated Interim Financial Statements which are available on the Company's website (www.nuvopharmaceuticals.com).


Three months ended

Six months ended


June 30,

2018

June 30,

2017

 

Change

June 30,

2018

June 30,

2017


Change

(in thousands, except gross margin)

$

$

$

$

$

$

Product Sales

5,349

2,786

2,563

9,104

9,439

(335)

Other Revenue

526

314

212

1,202

643

559

Total Operating Expenses

4,695

3,247

1,448

9,544

7,963

1,581

Gross Margin % on Product Sales

56%

48%

8%

53%

55%

(2)%

Net Income (Loss)

1,054

(203)

1,257

885

1,993

(1,108)

Adjusted EBITDA

1,851

(114)

1,965

2,409

2,184

225

 

Total revenue, consisting of product sales, license and contract revenue for the three months ended June 30, 2018 was $5.9 million compared to $3.1 million for the three months ended June 30 , 2017.  The increase in total revenue was primarily related to an increase in Pennsaid 2% product sales to our U.S. partner, Horizon Pharma plc.  Total revenue for the six months ended June 30, 2018 was $10.3 million compared to $10.1 million for the comparative six-month period.

Total operating expenses for the three months ended June 30, 2018 were $4.7 million compared to $3.2 million for the three months ended June 30 , 2017.  The increase in operating expenses was primarily attributable to an increase in cost of goods sold (COGS), general and administrative (G&A) expenses and depreciation and amortization.  Total operating expenses for the six months ended June 30, 2018 were $9.5 million , an increase from $8.0 million for the six months ended June 30 , 2017. 

COGS for the three months ended June 30, 2018 was $2.3 million compared to $1.5 million for the three months ended June 30 , 2017.  Gross margin on product sales was $3.0 million or 56% for the three months ended June 30, 2018 compared to a gross margin of $1.3 million or 48% for the three months ended June 30 , 2017.  For the six months ended June 30, 2018, COGS was $4.3 million compared to $4.2 million in the comparative six-month period.  Gross margin on product sales for the six months ended June 30, 2018 was $4.9 million or 53% compared to $5.2 million or 55% for the six months ended June 30, 2017.  The Company's gross margin on product sales was impacted by the volume and mix of products sold during the current and comparative three and six-month periods.  The Company's gross margin was also impacted by the Canadian dollar versus the U.S. dollar, the currency in which it earns certain product revenues and sources select Pennsaid 2% and Pennsaid raw materials.

G&A expenses were $1.9 million for the three months ended June 30, 2018 compared to $1.6 million for the three months ended June 30 , 2017.  G&A expenses were $4.3 million for the six months ended June 30, 2018 compared to $3.3 million for the six months ended June 30, 2017.  The increase in both the current three and six-month periods was attributable to compensation and stock-based compensation (SBC) associated with an increased employee headcount resulting from the strengthening of the executive and senior management team to facilitate the Company's growth strategy.  Furthermore, the Company recognized costs to support the transition and establishment of the Resultz business and in scientific and regulatory costs associated with the advancement of the Company's Pennsaid 2% European regulatory strategy, the majority of which are one-time in nature.

For the three and six months ended June 30, 2018 , the Company recognized non-cash costs of $0.5 million and $1.0 million in amortization relating to the Resultz patents.

Net income for the three months ended June 30, 2018 was $1.1 million compared to a net loss of $0.2 million for the three months ended June 30 , 2017.  In the current quarter, the increase was primarily attributable to a $1.7 million increase in gross margin and a $0.2 million increase in other revenue, offset by a $0.5 million increase in amortization and a $0.1 million increase in the fair value remeasurement of the Company's contingent and variable consideration.  Net income for the six months ended June 30, 2018 was $0.9 million compared to $2.0 million for the six months ended June 30 , 2017. 

Adjusted EBITDA increased to $1.9 million for the three months ended June 30, 2018 compared to $(0.1) million for the three months ended June 30 , 2017.  The increase in Adjusted EBITDA for the current quarter was primarily attributable to an increase in gross margin and an increase in other revenue related to the Resultz sales-based royalties.  Adjusted EBITDA increased to $2.4 million for the six months ended June 30, 2018 compared to $2.2 million for the comparative six-month period. 

Cash and short-term investments were $8.7 million as at June 30, 2018 compared to $6.5 million as at March 31 , 2018.  The increase in cash was primarily related to an increase in cash provided by operations.

The number of common shares outstanding as at June 30, 2018 was 11,368,455.

Non-IFRS Financial Measures

Adjusted EBITDA
EBITDA is a non-IFRS financial measure.  The term EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.  The Company defines Adjusted EBITDA as net income before net interest income, plus income tax expense (recovery), depreciation and amortization and SBC.  Management believes Adjusted EBITDA is a useful supplemental measure from which to determine the Company's ability to generate cash available for working capital, capital expenditures and income taxes.

The following is a summary of how EBITDA and Adjusted EBITDA are calculated:


Three Months Ended

June 30

Six Months Ended
June 30


2018

2017

2018

2017

in thousands

$

$

$

$

Net income (loss)

1,054

(203)

885

1,993

Add back:






Income tax expense (recovery)

46

-

(128)

-


Net interest income

(9)

(34)

(30)

(72)


Depreciation and amortization

611

58

1,225

112

EBITDA

1,702

(179)

1,952

2,033

Add back:






Stock-based compensation

149

65

457

151

Adjusted EBITDA

1,851

(114)

2,409

2,184

 

Management to Host Conference Call/Webcast
Management will host a conference call to discuss the results today ( Thursday, August 2, 2018 ) at 8:30 a.m. ET .  To participate in the conference call, please dial 1 888 390 0546 or 416 764 8688.  Please call in 15 minutes prior to the call to secure a line.  You will be put on hold until the conference call begins.

A taped replay of the conference call will be available two hours after the live conference call and will be accessible until August 9, 2018 by calling 1 888 390 0541 or 416 764 8677 playback passcode 566651.

A live audio webcast of the conference call will be available through www.nuvopharmaceuticals.com.  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities.  Nuvo has four commercial products that are available in a number of countries: Pennsaid® 2%, Pennsaid, Resultz® and the heated lidocaine/tetracaine patch.  Nuvo manufactures Pennsaid 2% for the U.S market, Pennsaid for the global market and the bulk drug product for the HLT Patch at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes , Québec.  The Company's focus is to maximize the value of Pennsaid 2% and Resultz through out-licensing to commercial partners in international markets and identifying new opportunities to acquire additional, revenue generating or late-stage products or businesses to further diversify the Company's existing product portfolio.  For additional information, please visit www.nuvopharmaceuticals.com.

Forward-Looking Statements
This Press Release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Nuvo's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, readers should not rely on any of these forward-looking statements. Important factors that could cause Nuvo's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risk factors included in Nuvo's most recent Annual Information Form dated March 22, 2018 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Nuvo with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on Nuvo's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Nuvo or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements.

Any forward-looking statement made by the Company in this Press Release is based only on information currently available to it and speaks only as of the date on which it is made. Except as required by applicable securities laws, Nuvo undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-announces-2018-second-quarter-results-300690797.html

SOURCE Nuvo Pharmaceuticals Inc.


View original content with multimedia: http://www.newswire.ca/en/releases/archive/August2018/02/c4499.html

  • There’s a Huge Flaw in Valuing AMD Stock Like Amazon or Netflix
    Finance
    InvestorPlace

    There’s a Huge Flaw in Valuing AMD Stock Like Amazon or Netflix

    This year has been an undeniably good one for Advanced Micro Devices (NASDAQ:AMD) shareholders. The AMD stock price is up 165% year-to-date, and seems to be dealing with recent headwinds relatively well. Although the turnaround is real, the market’s valuation of AMD stock has been exceedingly generous.

  • Here's everyone who has dropped out of Saudi Arabia's 'Davos of the Middle East'
    Finance
    Yahoo Finance

    Here's everyone who has dropped out of Saudi Arabia's 'Davos of the Middle East'

    U.S. Treasury Secretary Steven Mnuchin tweeted Thursday that he will not be attending the Future Investment Initiative in Saudi Arabia next week. The news comes after prominent members of the world’s business community have been dropping out of Saudi

  • What happens if you win Mega Millions' $970M jackpot?
    News
    Associated Press

    What happens if you win Mega Millions' $970M jackpot?

    Despite the terrible odds — one in 302.5 million for those keeping score at home — someone will eventually match all six numbers and win the Mega Millions jackpot, which now stands at $970 million. Here are some answers for someone holding that prized lottery ticket for what would be the second-largest lottery jackpot in U.S. history. Lottery officials recommend winners take a deep breath, put their winning ticket in a safe spot and consult with a reputable financial planner before popping over to the lottery headquarters.

  • Finding a Cure for Kinder Morgan’s Frustration
    Business
    Bloomberg

    Finding a Cure for Kinder Morgan’s Frustration

    Rising profits – Ebitda was up 6 percent, year over year – and that Canadian pipeline sale have helped address Kinder Morgan’s biggest problem, its crushing debt. Thankfully, it provided a strong signal on Wednesday evening that it would.

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • Twitter (TWTR) Q3 Earnings Preview: What to Know Ahead of the Release
    Business
    Zacks

    Twitter (TWTR) Q3 Earnings Preview: What to Know Ahead of the Release

    Twitter (TWTR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 25, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Business
    CNBC

    Goldman Sachs sees a correction coming for chipmakers but still likes Nvidia

    "We foresee a cyclical correction approaching and recommend investors to stay selective in Semis," Goldman Sachs said in a note Thursday. Nvidia is Goldman's top choice in the industry. Goldman Sachs warned clients about a downturn coming for the semiconductor sector, but still recommends some chip stocks.

  • Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight
    Politics
    Time

    Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight

    To understand what it means to be famous like Stormy Daniels, for the reasons she is famous, spend time with her in a public space. On Oct. 15, a California judge threw out the defamation case she filed against Donald Trump. Over the past year, Daniels, 39, has become the Zelig of White House scandals.

  • Cramer's lightning round: For growth and yield, go with V...
    KHC
    CNBC Videos

    Cramer's lightning round: For growth and yield, go with V...

    Jim Cramer speeds through his take on callers' favorite stocks, including his favorite pick for "decent growth with good yield."

  • 7 Stocks Warren Buffett Can’t Stop Buying
    Finance
    InvestorPlace

    7 Stocks Warren Buffett Can’t Stop Buying

    Sometimes identifying the best stocks to buy can be difficult, but you could do a lot worse than checking out the stocks selected by one of the world’s savviest hedge fund managers — Warren Buffett. Buffett’s stock picks are a popular source for investors, and for good reason. The billionaire Buffett is many things: He’s among the world’s most successful fund managers, a legendary philanthropist and owns more than 60 companies.

  • Aurora Cannabis Gets License for Aurora Sky Facility
    Finance
    Market Realist

    Aurora Cannabis Gets License for Aurora Sky Facility

    Key Updates from the Cannabis Sector after Legalization in Canada (Continued from Prior Part) Aurora Sky license On October 17, Aurora Cannabis (ACB) (ACBFF) announced that it received sales licenses from Health Canada. Aurora Cannabis stated that with

  • Robinhood fires back after criticism
    SPY
    Yahoo Finance Video

    Robinhood fires back after criticism

    When Robinhood launched in 2015, it was touted as an app that allows commission-free trading for everything from stocks to ETFs to cryptocurrencies. But a report from Bloomberg says Robinhood makes more than 40 percent of its revenue from selling its data to high-frequency trading firms. Yahoo Finance's Seana Smith, Dan Roberts and Adam Shapiro talk with Robinhood co-founder Vlad Tenev.

  • Finance
    CNBC

    China's stock market is getting pummeled and history shows that is bad news for US markets

    U.S. stocks are lower about 70 percent of the time in periods when there are big drops of 10 percent or more in Shanghai stocks, according to analytics firm Kensho. The main U.S. indexes lose about 5 percent when Shanghai stocks fall 10 percent or more in a 30-day period. Big blue chips, like Goldman and Caterpillar are among the losers, but copper and oil also fall hard when Shanghai sees a big decline.

  • Markets think the midterms could be as big as the presidential election
    Finance
    Yahoo Finance

    Markets think the midterms could be as big as the presidential election

    The midterm elections are less than three weeks away. According to strategists at Barclays, the options market is pricing in a 1.6% swing on election night, a modest swing given the recent volatility we’ve seen in the stock market.

  • Why American Airlines Group Stock Jumped 6% -- Then Gave Most of It Back
    Business
    Motley Fool

    Why American Airlines Group Stock Jumped 6% -- Then Gave Most of It Back

    Shares of American Airlines Group (NASDAQ: AAL) popped 6.4% in early trading Wednesday before retracting to close the day up less than 1% -- just 0.9%, to be precise. An upgrade assigned to the stock by Deutsche Bank appears to be the primary reason for the move. A Deutsche Bank analyst upgraded American Airlines stock from "hold" to "buy" on Wednesday, as we're told by our friends at StreetInsider.com.

  • Business
    U.S.News & World Report

    7 Oil Stocks With at Least 25 Percent Upside

    Oil prices may be nearing a peak. With both Brent and West Texas Intermediate oil prices bouncing higher in recent months, additional upside to oil prices may be limited in the near term. According to Bank of America analyst Doug Leggate, oil investors should now shift gears from identifying recovery story oil stocks and focus on oil stocks that offer a compelling value and/or high dividend yield.

  • Uber driver charged with kidnapping New York woman
    News
    Associated Press

    Uber driver charged with kidnapping New York woman

    An Uber driver in New York City kidnapped a woman who fell asleep in his vehicle, groped her in the back seat and then left her on the side of a highway in Connecticut, federal authorities said Tuesday. Harbir Parmar, 24, of Queens, was charged in U.S. District Court with kidnapping. "The presumption of innocence remains with my client," Parmar's lawyer, Susanne Brody, told The New York Times at the courthouse after the hearing.

  • Don't Fall Into These 2 Yield Traps: This Stock Is a Better Buy
    Business
    Motley Fool

    Don't Fall Into These 2 Yield Traps: This Stock Is a Better Buy

    For example, USA Compression Partners LP (NYSE: USAC) and CSI Compressco LP (NASDAQ: CCLP) offer investors yields of 12% and 13%, respectively, but they provide a niche service, and results can be volatile. Leverage can be great when things are going well, but can cause problems when times are tough.

  • Intel restructures manufacturing organization
    Finance
    American City Business Journals

    Intel restructures manufacturing organization

    Chip giant Intel is restructuring its technology and manufacturing business group as it chases more connected device markets and grapples with delays on its next chip generation. In a memo to employees, reviewed by the Business Journal, Group President and Chief Engineering Officer Murthy Renduchintala described splitting the technology and manufacturing business into three groups. The three new groups are technology development, manufacturing and operations and global supply chain.

  • Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment
    Finance
    American City Business Journals

    Jamal Khashoggi's brutal death brings to question an era of Bay Area tech investment

    New details have emerged about the killing of journalist Jamal Khashoggi by Saudi agents — involving his beheading and dismemberment upon entering the Saudi consulate in Istanbul, Turkey — thanks to audio files described by Turkish officials. As evidence mounts of the Washington Post columnist’s gruesome death tied to Saudi Arabia, Bay Area tech companies, which have gobbled up billions in funding from the kingdom in recent years, could see that money river dry up as Saudi investment becomes increasingly toxic. President Donald Trump has criticized those rushing to condemn the nation, telling the Associated Press: "You know, you’re guilty until proven innocent." Yet even still, Japanese investor Softbank isn’t stomaching the brutal killing tied to its major investment fund so easily.

  • The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse
    Business
    Business Insider

    The same question that can chart a path to early retirement is the one Warren Buffett used to build Berkshire Hathaway into a powerhouse

    Inversion is a mental model that involves flipping your outlook to prevent the opposite of what you want to happen from happening. Warren Buffett and his business partner Charlie Munger employed inversion as a business strategy to build Berkshire Hathaway into a powerhouse. In a recent podcast with Brandon of the Mad Fientist, who retired early at 34, productivity expert James Clear said the same strategy Buffett used can help set someone on the path for early retirement.

  • Is Tilray a Better Marijuana Stock to Buy Than Aurora Cannabis?
    Business
    Motley Fool

    Is Tilray a Better Marijuana Stock to Buy Than Aurora Cannabis?

    Marijuana users are cheering the legalization of marijuana for recreational use in Canada, but it's not just pot advocates who are excited. Investors are also upbeat because the recreational market for marijuana represents a massive opportunity for sales growth for leading Canadian cannabis companies, including Tilray Inc. (NASDAQ: TLRY) and Aurora Cannabis (NASDAQOTH: ACBFF). Medical marijuana has been legal in Canada for years, and while medical marijuana sales total in the hundreds of millions of dollars annually, the potential market opportunity associated with recreational use is significantly bigger.

  • How the Recent Sell-Off Impacted AT&T’s Technical Indicators
    Finance
    Market Realist

    How the Recent Sell-Off Impacted AT&T’s Technical Indicators

    What Investors Should Know about AT&T’s Growth Prospects (Continued from Prior Part) AT&T’s moving averages Now let’s look at AT&T’s (T) technical indicators and compare them to its peers in the telecom space. The sell-off of AT&T stock in October saw

  • Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage
    Finance
    Market Realist

    Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage

    Kinder Morgan Beats Q3 Earnings Estimates, Improves Leverage Kinder Morgan’s third-quarter results Kinder Morgan (KMI) announced its third-quarter results on October 17 after the markets closed. The company announced an adjusted EPS of $0.21—up ~40%

  • Business
    Reuters

    Nucor profit miss, steel market oversupply worries dent shares

    Nucor Corp posted a quarterly profit short of analysts' forecasts on Thursday and investor concerns that the U.S. steel market may be grappling with oversupply, undermining President Donald Trump's tariffs on imported steel, sent the company's shares lower. Shares of the largest steel producer in the United States fell as much as 3.7 percent to $56.91, as a dip in steel shipments from the second quarter put investors on alert that the market may be oversupplied. Nucor posted a profit that nearly tripled in the third quarter as a strong economy and the 25-percent tariff imposed in March boosted shipments and drove prices for its steel 23 percent higher.